Skip to main content
Top
Published in: Calcified Tissue International 4/2007

01-04-2007

Glomerular Filtration Rate Is a Major Determinant of the Relationship between 25-Hydroxyvitamin D and Parathyroid Hormone

Authors: S. Patel, S. Hyer, J. Barron

Published in: Calcified Tissue International | Issue 4/2007

Login to get access

Abstract

The reference range for 25-hydroxyvitamin D (25-OHD) remains uncertain, and it is not clear as to whether interpretation of circulating 25-OHD would be aided by simultaneous measurement of serum parathyroid hormone (PTH). We wanted to define the level of serum 25-OHD associated with a raised serum PTH and to examine the determinants of the relationship between serum 25-OHD and serum PTH concentration. We retrospectively examined data for patients who had a 25-OHD measurement and other biochemical variables over a 12-month period in our center. We found that 28% of patients had a serum 25-OHD level below 50 nmol/L and serum PTH level in the normal reference range, whereas 24% had a serum 25-OHD level below 50 nmol/L with a serum PTH value above the normal reference range. At a serum 25-OHD level of 80 nmol/L, 1.5% had an elevated serum PTH and, at 50 nmol/L, 8% had raised serum PTH. Further examination showed that for patients with low serum 25-OHD, low glomerular filtration rate (GFR) was a major determinant of the PTH response. These data confirm an inverse correlation between serum 25-OHD and serum PTH. Minimal numbers of patients (1.5% of the study group) have a raised serum PTH at a serum 25-OHD level of 80 nmol/L. GFR is a major determinant of the PTH response to decreasing serum levels of 25-OHD.
Literature
1.
go back to reference Hollis B (2004) The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89:3149–3151PubMedCrossRef Hollis B (2004) The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89:3149–3151PubMedCrossRef
2.
go back to reference Binkley N, Krueger D, Cowgill CS, et al. (2004) Assay variation confounds the diagnosis of hypovitaminosis D. J Clin Endocrinol Metab 89:3152–3157PubMedCrossRef Binkley N, Krueger D, Cowgill CS, et al. (2004) Assay variation confounds the diagnosis of hypovitaminosis D. J Clin Endocrinol Metab 89:3152–3157PubMedCrossRef
3.
go back to reference Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716PubMedCrossRef Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716PubMedCrossRef
5.
go back to reference Lips P (2004) Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89/90:611–614CrossRef Lips P (2004) Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89/90:611–614CrossRef
6.
go back to reference Vieth R, Fuleihan GE (2005) There is no lower threshold level for parathyroid hormone as 25-hydroxyvitamin D concentrations rise. J Endocrinol Invest 28:183–186PubMed Vieth R, Fuleihan GE (2005) There is no lower threshold level for parathyroid hormone as 25-hydroxyvitamin D concentrations rise. J Endocrinol Invest 28:183–186PubMed
7.
go back to reference Heaney RP (2005) Serum 25-hydroxyvitamin D and parathyroid hormone exhibit threshold behaviour. J Endocrinol Invest 28:180–182PubMed Heaney RP (2005) Serum 25-hydroxyvitamin D and parathyroid hormone exhibit threshold behaviour. J Endocrinol Invest 28:180–182PubMed
8.
go back to reference Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly. Endocr Rev 22:477–501PubMedCrossRef Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly. Endocr Rev 22:477–501PubMedCrossRef
9.
10.
go back to reference Bates CJ, Carter GD, Mishra GD, O’Shea D, Jones J, Prentice A (2003) In a population study, can parathyroid hormone aid the definition of adequate vitamin D status? A study of people aged 65 years and over from the British National Diet and Nutrition Survey. Osteoporos Int 14:152–159PubMed Bates CJ, Carter GD, Mishra GD, O’Shea D, Jones J, Prentice A (2003) In a population study, can parathyroid hormone aid the definition of adequate vitamin D status? A study of people aged 65 years and over from the British National Diet and Nutrition Survey. Osteoporos Int 14:152–159PubMed
11.
go back to reference Weaver CM, Fleet JC (2004) Vitamin D requirements: current & future. Am J Clin Nutr 80:1735S–1739SPubMed Weaver CM, Fleet JC (2004) Vitamin D requirements: current & future. Am J Clin Nutr 80:1735S–1739SPubMed
12.
go back to reference Favus MJ (2005) Postmenopausal osteoporosis and the detection of so-called secondary causes of low bone density. J Clin Endocrinol Metab 90:3800–3801PubMedCrossRef Favus MJ (2005) Postmenopausal osteoporosis and the detection of so-called secondary causes of low bone density. J Clin Endocrinol Metab 90:3800–3801PubMedCrossRef
14.
go back to reference Tanpricha V, Pearce EN, Chen TC, Holick MF (2002) Vitamin D insufficiency among free-living healthy young adults. Am J Med 112:659–662CrossRef Tanpricha V, Pearce EN, Chen TC, Holick MF (2002) Vitamin D insufficiency among free-living healthy young adults. Am J Med 112:659–662CrossRef
15.
go back to reference Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582PubMedCrossRef Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 14:577–582PubMedCrossRef
16.
go back to reference Vieth R, Ladak Y, Walfish PG (2003) Age related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88:185–191PubMedCrossRef Vieth R, Ladak Y, Walfish PG (2003) Age related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88:185–191PubMedCrossRef
17.
go back to reference Sahota O, Mundey MK, San P, et al. (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319PubMedCrossRef Sahota O, Mundey MK, San P, et al. (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319PubMedCrossRef
18.
go back to reference Pepe J, Romagnoli E, Nofroni I, et al. (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects Osteoporos Int 16:805–812PubMedCrossRef Pepe J, Romagnoli E, Nofroni I, et al. (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects Osteoporos Int 16:805–812PubMedCrossRef
19.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–47020PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–47020PubMed
20.
go back to reference National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis 39:S1–S200CrossRef National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis 39:S1–S200CrossRef
21.
go back to reference Sahota O, Gaynor K, Harwood RH, Hosking DJ (2001) Hypovitaminosis D and “functional hypoparathyroidism” – the NoNOF (Nottingham Neck of Femur) study. Age Ageing 30:467–472PubMedCrossRef Sahota O, Gaynor K, Harwood RH, Hosking DJ (2001) Hypovitaminosis D and “functional hypoparathyroidism” – the NoNOF (Nottingham Neck of Femur) study. Age Ageing 30:467–472PubMedCrossRef
22.
go back to reference Souberbielle JC, Cormier C, Kindermans C, et al. (2001) Vitamin D status and redefining serum parathyroid hormone reference in the elderly. J Clin Endocrinol Metab 86:3086–3090PubMedCrossRef Souberbielle JC, Cormier C, Kindermans C, et al. (2001) Vitamin D status and redefining serum parathyroid hormone reference in the elderly. J Clin Endocrinol Metab 86:3086–3090PubMedCrossRef
23.
go back to reference Sahota O, Mundey MK, San P, Godber IM, Hosking DJ (2006) Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int 17:1013–1021PubMedCrossRef Sahota O, Mundey MK, San P, Godber IM, Hosking DJ (2006) Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int 17:1013–1021PubMedCrossRef
24.
go back to reference Zemel MB (2002) Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 21:146S–151SPubMed Zemel MB (2002) Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 21:146S–151SPubMed
25.
go back to reference McCarty MF, Thomas CA (2003) PTH excess may promote weight gain by impeding catecholamine-induced liplysis – implications for the impact of calcium, vitamin D and alcohol on body weight. Med Hypotheses 61:535–542PubMedCrossRef McCarty MF, Thomas CA (2003) PTH excess may promote weight gain by impeding catecholamine-induced liplysis – implications for the impact of calcium, vitamin D and alcohol on body weight. Med Hypotheses 61:535–542PubMedCrossRef
26.
go back to reference Garber AJ (1983) Effects of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat. J Clin Invest 71:1806–1821PubMedCrossRef Garber AJ (1983) Effects of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat. J Clin Invest 71:1806–1821PubMedCrossRef
27.
go back to reference Sambrook PN, Chen JS, March LM, et al. (2004) Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxyvitamin D status, bone mass and renal function in the frail and very old. J Clin Endocrinol Metab 89:5469–5476CrossRef Sambrook PN, Chen JS, March LM, et al. (2004) Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxyvitamin D status, bone mass and renal function in the frail and very old. J Clin Endocrinol Metab 89:5469–5476CrossRef
28.
go back to reference Sambrook PN, Chen C, March LM, et al. (2004) Serum parathyroid hormone predicts time to first fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 89:1572–1576PubMedCrossRef Sambrook PN, Chen C, March LM, et al. (2004) Serum parathyroid hormone predicts time to first fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 89:1572–1576PubMedCrossRef
Metadata
Title
Glomerular Filtration Rate Is a Major Determinant of the Relationship between 25-Hydroxyvitamin D and Parathyroid Hormone
Authors
S. Patel
S. Hyer
J. Barron
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 4/2007
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-007-9001-9

Other articles of this Issue 4/2007

Calcified Tissue International 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine